Bryn Mawr Capital Management LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Bryn Mawr Capital Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,850 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.

A number of other institutional investors have also modified their holdings of GILD. OFI Invest Asset Management acquired a new stake in Gilead Sciences during the third quarter worth about $26,000. Tompkins Financial Corp raised its stake in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the period. Fortitude Family Office LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $29,000. Rakuten Securities Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth about $33,000. Finally, Financial Connections Group Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GILD. UBS Group dropped their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday. Wells Fargo & Company decreased their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Morgan Stanley decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Oppenheimer restated an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $83.87.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Up 0.2 %

Gilead Sciences stock opened at $65.42 on Friday. The firm has a 50 day simple moving average of $71.28 and a 200-day simple moving average of $76.25. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock has a market capitalization of $81.45 billion, a PE ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $64.63 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $1.37 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 3.82 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.